However, there are still some limitations in this study, the use of activator and inhibitor on the PI3K/AKT pathway was lacked in in vivo experiment, thus additional studies are required to further delineate the mechanistic actions of formononetin on HCC. This evidence concerns the gene PIK3CG and hepatocellular carcinoma.